A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 761 in Subjects With Asthma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Amgen
- 11 Jun 2014 Status changed from active, no longer recruiting to discontinued.
- 10 Jan 2014 Planned End Date changed from 1 May 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov record.
- 27 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov.